List your practice on InjuredCare | Log in / Sign up

Cancer Related to Breast Implants

Cancer Related to Breast Implants

The U.S. Food and Drug Administration (FDA) has given approval to two different types of breast implants for sale in the United States. The breast implants both utilize an exterior silicon shell, though one is filled with a gel and the other with a saline solution. The exterior of some implants is textured, while the others are smooth on the outside. Both products have been used for reconstructive and cosmetic surgery.

The FDA has conducted public hearings to gather information on the health risks associated with both types of implants. Among the specific health concerns is a potential link to a rare type of cancer known as anaplastic large cell lymphoma (ALCL).

ALCL is a rare cancer that can manifest anywhere in the body, but more characteristically in the lymph nodes and on the skin. Most of the research conducted thus far supports a conclusion that the ALCL does not develop in the breast itself, but in the scar tissue surrounding the implant incision. Researchers also believe that risk of cancer is greater with the textured implants and may be as high as one in every 4,000 patients. There's no conclusive evidence to date indicating whether there's a greater risk with the saline-filled or the gel-filled implants.

Studies show that, when caught early, ALCL is treatable and curable. The common method of care is the surgical removal of both implants and any existing cancer.

Related Articles

  • Valsartan

    Valsartan

    Valsartan, commonly sold under the trade name Diovan, is a pharmaceutical product marketed and sold for the treatment of high blood pressure, diabetic kidney disease, and heart fai Read More...

  • Toxic Epidermal Necrolysis

    Toxic Epidermal Necrolysis

    Toxic Epidermal Necrolysis (TEN) Serious and/or Life-Threatening Skin Reactions or Lesions Also known as Lyell or Lyell's syndrome, toxic epidermal necrolysis (TEN) first appears Read More...

  • Onglyza

    Onglyza

    Onglyza was co-formulated by Bristol-Myers Squibb and AstraZeneca in 2007. On July 31, 2009, it was approved by the FDA for treatment of type-2 diabetes. Its key active ingredient, Read More...

© 2015-2022 LawConnect, Inc. All rights reserved.

CONCEPT, DESIGN and HOSTING BY GETLEGAL.COM’S WEB SERVICES TEAM..